Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for REC.MI and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for REC.MI and 80,000+ other tickers.
See exactly how REC.MI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for REC.MI and 80,000+ other tickers.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for…
Consolidated net revenue of € 713. 4 million in the first quarter of 2026,4. 9% or8. 7% on a like-for-like basis(3) at constant exchange rates (CER); adverse FX impact of € 29. 1 million (-4.
Ricavi netti consolidati nel primo trimestre del 2026 pari a € 713,4 milioni,4,9% o8,7% a perimetro omogeneo(3) e a cambi costanti; impatto negativo dei cambi di € 29,1 milioni (-4,3%)EBITDA(1) pari a € 283,6 milioni,5,0%, con un'incidenza sui ricavi netti del 39,7%Utile netto rettificato(2) pari a € 188,1 milioni,7,2%, con un'incidenza sui ricavi netti del 26,4%Utile netto pari a € 153,1 milioni,22,4% Free cash flow(4) pari a € 92,1 milioni, -€ 66,7 milioni rispetto all'anno precedenteDebito netto(5) pari a € 1.
RECORDATI FIRST NINE MONTHS 2025 RESULTS:REVENUE12. 2%, EBITDA(1)11. 8%, ADJUSTED NET INCOME(2)10. 7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1. 2 BILLION Consolidated net revenue of € 1,956.